Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 1.17
WST's Cash-to-Debt is ranked lower than
57% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. WST: 1.17 )
Ranked among companies with meaningful Cash-to-Debt only.
WST' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.24 Max: 1.17
Current: 1.17
0
1.17
Equity-to-Asset 0.68
WST's Equity-to-Asset is ranked higher than
61% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. WST: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
WST' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.49 Max: 0.68
Current: 0.68
0.35
0.68
Debt-to-Equity 0.18
WST's Debt-to-Equity is ranked higher than
66% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.35 vs. WST: 0.18 )
Ranked among companies with meaningful Debt-to-Equity only.
WST' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.17  Med: 0.52 Max: 1.09
Current: 0.18
0.17
1.09
Debt-to-EBITDA 0.72
WST's Debt-to-EBITDA is ranked higher than
78% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. WST: 0.72 )
Ranked among companies with meaningful Debt-to-EBITDA only.
WST' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.79  Med: 1.95 Max: 2.51
Current: 0.72
0.79
2.51
Interest Coverage 31.30
WST's Interest Coverage is ranked lower than
55% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.21 vs. WST: 31.30 )
Ranked among companies with meaningful Interest Coverage only.
WST' s Interest Coverage Range Over the Past 10 Years
Min: 5.4  Med: 7.99 Max: 24.3
Current: 31.3
5.4
24.3
Piotroski F-Score: 6
Altman Z-Score: 9.54
Beneish M-Score: -2.44
WACC vs ROIC
8.85%
15.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 14.19
WST's Operating Margin % is ranked higher than
73% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.72 vs. WST: 14.19 )
Ranked among companies with meaningful Operating Margin % only.
WST' s Operating Margin % Range Over the Past 10 Years
Min: 8.21  Med: 10.07 Max: 13.04
Current: 14.19
8.21
13.04
Net Margin % 12.12
WST's Net Margin % is ranked higher than
75% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.03 vs. WST: 12.12 )
Ranked among companies with meaningful Net Margin % only.
WST' s Net Margin % Range Over the Past 10 Years
Min: 5.91  Med: 6.91 Max: 9.52
Current: 12.12
5.91
9.52
ROE % 15.85
WST's ROE % is ranked higher than
74% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.68 vs. WST: 15.85 )
Ranked among companies with meaningful ROE % only.
WST' s ROE % Range Over the Past 10 Years
Min: 9.65  Med: 13.52 Max: 17.69
Current: 15.85
9.65
17.69
ROA % 10.59
WST's ROA % is ranked higher than
79% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.36 vs. WST: 10.59 )
Ranked among companies with meaningful ROA % only.
WST' s ROA % Range Over the Past 10 Years
Min: 5.09  Med: 6.34 Max: 8.42
Current: 10.59
5.09
8.42
ROC (Joel Greenblatt) % 21.74
WST's ROC (Joel Greenblatt) % is ranked higher than
65% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.63 vs. WST: 21.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
WST' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.75  Med: 17.48 Max: 21.35
Current: 21.74
12.75
21.35
3-Year Revenue Growth Rate 1.60
WST's 3-Year Revenue Growth Rate is ranked lower than
60% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.90 vs. WST: 1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
WST' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.9  Med: 5.1 Max: 17.8
Current: 1.6
-2.9
17.8
3-Year EBITDA Growth Rate 3.30
WST's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. WST: 3.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
WST' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.3  Med: 6.5 Max: 39.8
Current: 3.3
-20.3
39.8
3-Year EPS without NRI Growth Rate 6.80
WST's 3-Year EPS without NRI Growth Rate is ranked higher than
53% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. WST: 6.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
WST' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.6  Med: 7.1 Max: 73.1
Current: 6.8
-38.6
73.1
GuruFocus has detected 4 Warning Signs with West Pharmaceutical Services Inc WST.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WST's 30-Y Financials

Financials (Next Earnings Date: 2018-02-16)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

WST Guru Trades in Q4 2016

Chuck Royce 23,000 sh (New)
Paul Tudor Jones Sold Out
Ken Fisher 1,170,631 sh (-4.24%)
Ron Baron 2,138,775 sh (-5.30%)
Ruane Cunniff 373,781 sh (-11.94%)
Columbia Wanger 606,983 sh (-22.32%)
» More
Q1 2017

WST Guru Trades in Q1 2017

Caxton Associates 5,600 sh (New)
Jim Simons 4,100 sh (New)
Chuck Royce 23,000 sh (unchged)
Ken Fisher 1,124,209 sh (-3.97%)
Columbia Wanger 580,216 sh (-4.41%)
Ron Baron 1,900,845 sh (-11.12%)
Ruane Cunniff 59,742 sh (-84.02%)
» More
Q2 2017

WST Guru Trades in Q2 2017

Eaton Vance Worldwide Health Sciences Fund 59,199 sh (New)
Jim Simons 318,600 sh (+7670.73%)
Chuck Royce 23,000 sh (unchged)
Ken Fisher 1,099,159 sh (-2.23%)
Ron Baron 1,806,120 sh (-4.98%)
Caxton Associates 5,000 sh (-10.71%)
Columbia Wanger 481,547 sh (-17.01%)
Ruane Cunniff 42,794 sh (-28.37%)
» More
Q3 2017

WST Guru Trades in Q3 2017

Jim Simons 420,500 sh (+31.98%)
Chuck Royce 23,000 sh (unchged)
Ron Baron 1,806,150 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 59,199 sh (unchged)
Caxton Associates Sold Out
Ruane Cunniff 41,383 sh (-3.30%)
Ken Fisher 1,062,304 sh (-3.35%)
Columbia Wanger 244,984 sh (-49.13%)
» More
» Details

Insider Trades

Latest Guru Trades with WST

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-09-30 Reduce -3.35%0.01%$84.54 - $96.75 $ 98.969%1,062,304
Ruane Cunniff 2017-09-30 Reduce -3.30%$84.54 - $96.75 $ 98.969%41,383
Ron Baron 2017-06-30 Reduce -4.98%0.04%$78.61 - $99.44 $ 98.968%1,806,120
Ken Fisher 2017-06-30 Reduce -2.23%$78.61 - $99.44 $ 98.968%1,099,159
Ruane Cunniff 2017-06-30 Reduce -28.37%0.01%$78.61 - $99.44 $ 98.968%42,794
Ron Baron 2017-03-31 Reduce -11.12%0.11%$79.58 - $87.7 $ 98.9618%1,900,845
Ken Fisher 2017-03-31 Reduce -3.97%0.01%$79.58 - $87.7 $ 98.9618%1,124,209
Ruane Cunniff 2017-03-31 Reduce -84.02%0.25%$79.58 - $87.7 $ 98.9618%59,742
Ron Baron 2016-12-31 Reduce -5.30%0.05%$70.57 - $85.3 $ 98.9626%2,138,775
Ken Fisher 2016-12-31 Reduce -4.24%0.01%$70.57 - $85.3 $ 98.9626%1,170,631
Ruane Cunniff 2016-12-31 Reduce -11.94%0.04%$70.57 - $85.3 $ 98.9626%373,781
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NYSE:STE, OSTO:GETI B, SZSE:002294, NYSE:HRC, NAS:HOLX, NYSE:CMD, NAS:ICUI, XSWX:STMN, TSE:7747, NAS:PODD, MIL:AMP, OSTO:LIFCO B, NYSE:COO, NYSE:RMD, ASX:ANN, NYSE:HAE, XTER:GXI, TSE:7733, TSE:7732, NYSE:HYH » details
Traded in other countries:WPS.Germany,
Headquarter Location:USA
West Pharmaceutical Services Inc develops, manufactures and sells packaging components and systems for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, and prefillable syringe components.

West Pharmaceutical Services Inc develops, manufactures and sells packaging components and systems for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, and prefillable syringe components.

Guru Investment Theses on West Pharmaceutical Services Inc

Baron Asset Fund Comments on West Pharmaceutical Services - Jan 30, 2017

Shares of West Pharmaceutical Services, Inc. (NYSE:WST), a manufacturer of packaging components and delivery devices for injectable drugs, gained after reporting impressive quarterly financial results. Management provided solid guidance for 2017 and reaffirmed its goals for strong growth through 2020. We continue to believe that West can double its earnings over the next five years, driven by sales of higher margin packaging components and proprietary products to the pharmaceutical and biotechnology industries.



From Barron Asset Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on West Pharmaceutical Services - Apr 26, 2016

West Pharmaceutical Services, Inc. (NYSE:WST) manufactures components and systems for the packaging and delivery of injectable drugs. West’s shares gained during the quarter after reporting strong financial results and providing solid earnings guidance for 2016. West’s products are frequently “designed in” as part of the regulatory approval process for its clients’ drugs, which makes it quite difficult for West’s products to be displaced throughout a drug’s lifecycle. There is a substantial development pipeline of injectable biologic drugs, and we believe this will allow West to experience double-digit growth rates in its main market for at least the next several years. We also believe that West will benefit from the increased sale of high-margin proprietary products, including newly-developed plastic syringes and wearable injectors for a new generation of high volume, high viscosity drugs. As a result, we believe that company has the potential to double its earnings during the next five years.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about West Pharmaceutical Services Inc

West to Showcase New Extensions of the SmartDose® Drug Delivery Platform at the PDA Universe of Pre-filled Syringes and Injection Devices
West to Host Third-Quarter 2017 Conference Call
Study Demonstrates Benefit of West's ID Adapter for Improving Intradermal Administration of Polio Vaccine
West Announces Fall Investor Conference Schedule
New Feature: Screening for Companies Using Technical Indicators You can now screen based on relative strength index, 6-month price index and simple moving averages
We are pleased to announce a new feature within our All-in-one Guru Screener: screening using technical indicators. Read more...
West Announces Increase to Quarterly Dividend
West Elects New Director to the Board
West to Present on Biologics Trends at InnoPack Pharma Confex
Insiders Roundup: Facebook, General Electric, Aetna The largest insider trades of the week
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “March 2017” and All Insider Sales to “$5,000,000+.” Read more...
West Announces Quarterly Dividend and Participation in Upcoming Investor Conferences

Ratios

vs
industry
vs
history
PE Ratio 39.58
WST's PE Ratio is ranked lower than
71% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.08 vs. WST: 39.58 )
Ranked among companies with meaningful PE Ratio only.
WST' s PE Ratio Range Over the Past 10 Years
Min: 12.28  Med: 23.95 Max: 64.85
Current: 39.58
12.28
64.85
Forward PE Ratio 33.78
WST's Forward PE Ratio is ranked lower than
78% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.51 vs. WST: 33.78 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 39.58
WST's PE Ratio without NRI is ranked lower than
71% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. WST: 39.58 )
Ranked among companies with meaningful PE Ratio without NRI only.
WST' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.28  Med: 23.86 Max: 64.85
Current: 39.58
12.28
64.85
Price-to-Owner-Earnings 83.79
WST's Price-to-Owner-Earnings is ranked lower than
87% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.51 vs. WST: 83.79 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WST' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.33  Med: 41.79 Max: 173.32
Current: 83.79
21.33
173.32
PB Ratio 5.58
WST's PB Ratio is ranked lower than
74% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. WST: 5.58 )
Ranked among companies with meaningful PB Ratio only.
WST' s PB Ratio Range Over the Past 10 Years
Min: 1.74  Med: 2.93 Max: 6.09
Current: 5.58
1.74
6.09
PS Ratio 4.78
WST's PS Ratio is ranked lower than
61% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.36 vs. WST: 4.78 )
Ranked among companies with meaningful PS Ratio only.
WST' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.67 Max: 4.91
Current: 4.78
1.02
4.91
Price-to-Free-Cash-Flow 71.76
WST's Price-to-Free-Cash-Flow is ranked lower than
92% of the 72 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.99 vs. WST: 71.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WST' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 18.49  Med: 53.2 Max: 381.09
Current: 71.76
18.49
381.09
Price-to-Operating-Cash-Flow 29.58
WST's Price-to-Operating-Cash-Flow is ranked lower than
68% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.95 vs. WST: 29.58 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WST' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.55  Med: 12.14 Max: 30.78
Current: 29.58
7.55
30.78
EV-to-EBIT 32.72
WST's EV-to-EBIT is ranked lower than
69% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.17 vs. WST: 32.72 )
Ranked among companies with meaningful EV-to-EBIT only.
WST' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.2  Med: 19.5 Max: 53.3
Current: 32.72
11.2
53.3
EV-to-EBITDA 22.98
WST's EV-to-EBITDA is ranked lower than
66% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.83 vs. WST: 22.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
WST' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.6  Med: 12.2 Max: 27.6
Current: 22.98
7.6
27.6
EV-to-Revenue 4.67
WST's EV-to-Revenue is ranked lower than
57% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. WST: 4.67 )
Ranked among companies with meaningful EV-to-Revenue only.
WST' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3  Med: 1.9 Max: 4.9
Current: 4.67
1.3
4.9
PEG Ratio 5.66
WST's PEG Ratio is ranked lower than
76% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. WST: 5.66 )
Ranked among companies with meaningful PEG Ratio only.
WST' s PEG Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.37 Max: 50.27
Current: 5.66
1.01
50.27
Shiller PE Ratio 65.51
WST's Shiller PE Ratio is ranked lower than
67% of the 51 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.91 vs. WST: 65.51 )
Ranked among companies with meaningful Shiller PE Ratio only.
WST' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.08  Med: 34.98 Max: 68.23
Current: 65.51
19.08
68.23
Current Ratio 2.59
WST's Current Ratio is ranked lower than
53% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. WST: 2.59 )
Ranked among companies with meaningful Current Ratio only.
WST' s Current Ratio Range Over the Past 10 Years
Min: 1.37  Med: 2.11 Max: 3.1
Current: 2.59
1.37
3.1
Quick Ratio 1.87
WST's Quick Ratio is ranked lower than
53% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. WST: 1.87 )
Ranked among companies with meaningful Quick Ratio only.
WST' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.51 Max: 2.28
Current: 1.87
0.85
2.28
Days Inventory 71.72
WST's Days Inventory is ranked higher than
83% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.23 vs. WST: 71.72 )
Ranked among companies with meaningful Days Inventory only.
WST' s Days Inventory Range Over the Past 10 Years
Min: 52.45  Med: 64.65 Max: 70.1
Current: 71.72
52.45
70.1
Days Sales Outstanding 58.70
WST's Days Sales Outstanding is ranked higher than
56% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.37 vs. WST: 58.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
WST' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.76  Med: 47.63 Max: 50.44
Current: 58.7
41.76
50.44
Days Payable 42.04
WST's Days Payable is ranked lower than
54% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.31 vs. WST: 42.04 )
Ranked among companies with meaningful Days Payable only.
WST' s Days Payable Range Over the Past 10 Years
Min: 29.33  Med: 39.47 Max: 46.32
Current: 42.04
29.33
46.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.54
WST's Dividend Yield % is ranked lower than
79% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.32 vs. WST: 0.54 )
Ranked among companies with meaningful Dividend Yield % only.
WST' s Dividend Yield % Range Over the Past 10 Years
Min: 0.51  Med: 1.16 Max: 2.01
Current: 0.54
0.51
2.01
Dividend Payout Ratio 0.21
WST's Dividend Payout Ratio is ranked higher than
89% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. WST: 0.21 )
Ranked among companies with meaningful Dividend Payout Ratio only.
WST' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.23  Med: 0.27 Max: 0.35
Current: 0.21
0.23
0.35
3-Year Dividend Growth Rate 8.40
WST's 3-Year Dividend Growth Rate is ranked lower than
52% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.50 vs. WST: 8.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
WST' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 1  Med: 7 Max: 13.7
Current: 8.4
1
13.7
Forward Dividend Yield % 0.57
WST's Forward Dividend Yield % is ranked lower than
80% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.32 vs. WST: 0.57 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.76
WST's 5-Year Yield-on-Cost % is ranked lower than
74% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. WST: 0.76 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WST' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.72  Med: 1.64 Max: 2.85
Current: 0.76
0.72
2.85
3-Year Average Share Buyback Ratio -1.40
WST's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.10 vs. WST: -1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WST' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: -1 Max: 4.8
Current: -1.4
-4.3
4.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 44.98
WST's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.73 vs. WST: 44.98 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
WST' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 43.78  Med: 112.93 Max: 2007.33
Current: 44.98
43.78
2007.33
Price-to-Tangible-Book 6.19
WST's Price-to-Tangible-Book is ranked lower than
61% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.82 vs. WST: 6.19 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
WST' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.2  Med: 2.82 Max: 6.87
Current: 6.19
1.2
6.87
Price-to-Intrinsic-Value-Projected-FCF 4.36
WST's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
80% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.18 vs. WST: 4.36 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WST' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.97  Med: 2.08 Max: 4.39
Current: 4.36
0.97
4.39
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.43
WST's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
76% of the 21 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. WST: 3.43 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
WST' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.6  Med: 1.5 Max: 8.34
Current: 3.43
0.6
8.34
Price-to-Median-PS-Value 2.87
WST's Price-to-Median-PS-Value is ranked lower than
94% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. WST: 2.87 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WST' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 0.7 Max: 2.79
Current: 2.87
0.36
2.79
Price-to-Peter-Lynch-Fair-Value 7.62
WST's Price-to-Peter-Lynch-Fair-Value is ranked lower than
95% of the 44 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.18 vs. WST: 7.62 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WST' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.67 Max: 8.3
Current: 7.62
0.54
8.3
Price-to-Graham-Number 3.30
WST's Price-to-Graham-Number is ranked lower than
60% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. WST: 3.30 )
Ranked among companies with meaningful Price-to-Graham-Number only.
WST' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.96  Med: 1.6 Max: 3.79
Current: 3.3
0.96
3.79
Earnings Yield (Greenblatt) % 3.06
WST's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. WST: 3.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WST' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 5.1 Max: 8.9
Current: 3.06
1.9
8.9
Forward Rate of Return (Yacktman) % 6.25
WST's Forward Rate of Return (Yacktman) % is ranked lower than
64% of the 97 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.48 vs. WST: 6.25 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WST' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.7  Med: 9.7 Max: 22.1
Current: 6.25
-3.7
22.1

More Statistics

Revenue (TTM) (Mil) $1,565.80
EPS (TTM) $ 2.50
Beta1.12
Short Percentage of Float3.91%
52-Week Range $77.97 - 103.36
Shares Outstanding (Mil)74.25

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) 2.43 2.93
EPS without NRI ($) 2.43 2.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}